Edwards Lifesciences Corporation (EW)
Company Info
Highlights
$45.88B
$2.42
32.32
4.36
$5.54B
$4.39B
$1.77B
$58.93 - $95.25
$80.97
1.43%
1.58
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
Loading data...
Returns By Period
Edwards Lifesciences Corporation (EW) returned 5.66% year-to-date (YTD) and -9.98% over the past 12 months. Over the past 10 years, EW delivered an annualized return of 13.59%, outperforming the S&P 500 benchmark at 10.85%.
EW
5.66%
3.40%
9.63%
-9.98%
-8.12%
0.87%
13.59%
^GSPC (Benchmark)
0.51%
3.96%
-2.00%
12.02%
12.68%
14.19%
10.85%
Monthly Returns
The table below presents the monthly returns of EW, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | -2.13% | -1.15% | 1.20% | 4.15% | 3.62% | 5.66% | |||||||
| 2024 | 2.91% | 8.16% | 12.60% | -11.40% | 2.62% | 6.31% | -31.74% | 10.96% | -5.67% | 1.55% | 6.48% | 3.76% | -2.91% |
| 2023 | 2.80% | 4.88% | 2.85% | 6.35% | -4.26% | 11.99% | -13.00% | -6.82% | -9.40% | -8.03% | 6.26% | 12.61% | 2.20% |
| 2022 | -15.71% | 2.90% | 4.76% | -10.14% | -4.66% | -5.71% | 5.73% | -10.38% | -8.29% | -12.34% | 6.65% | -3.42% | -42.41% |
| 2021 | -9.48% | 0.63% | 0.65% | 14.20% | 0.40% | 8.00% | 8.40% | 4.37% | -3.39% | 5.84% | -10.44% | 20.73% | 42.00% |
| 2020 | -5.76% | -6.83% | -7.92% | 15.31% | 3.32% | -7.74% | 13.46% | 9.48% | -7.01% | -10.19% | 17.02% | 8.75% | 17.32% |
| 2019 | 11.26% | -0.66% | 13.02% | -7.98% | -3.05% | 8.22% | 15.22% | 4.22% | -0.87% | 8.40% | 2.75% | -4.76% | 52.31% |
| 2018 | 12.31% | 5.60% | 4.38% | -8.72% | 7.81% | 6.02% | -2.14% | 1.26% | 20.70% | -15.22% | 9.76% | -5.46% | 35.90% |
| 2017 | 2.71% | -2.29% | 0.03% | 16.58% | 4.92% | 2.75% | -2.59% | -1.32% | -3.83% | -6.48% | 14.64% | -3.83% | 20.29% |
| 2016 | -0.98% | 11.24% | 1.39% | 20.41% | -7.26% | 1.25% | 14.83% | 0.56% | 4.69% | -21.02% | -12.99% | 13.10% | 18.64% |
| 2015 | -1.59% | 6.12% | 7.10% | -11.10% | 3.21% | 8.96% | 6.83% | -7.41% | 0.92% | 10.54% | 3.72% | -3.09% | 24.01% |
| 2014 | -0.97% | 7.13% | 6.32% | 9.84% | -0.33% | 5.71% | 5.14% | 9.98% | 2.91% | 18.37% | 7.24% | -1.77% | 93.70% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of EW is 37, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Edwards Lifesciences Corporation (EW) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Loading data...
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading data...
Worst Drawdowns
The table below displays the maximum drawdowns of the Edwards Lifesciences Corporation. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Edwards Lifesciences Corporation was 54.32%, occurring on Jul 25, 2024. The portfolio has not yet recovered.
The current Edwards Lifesciences Corporation drawdown is 40.14%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -54.32% | Dec 31, 2021 | 644 | Jul 25, 2024 | — | — | — |
| -50.48% | Sep 1, 2000 | 43 | Nov 1, 2000 | 165 | Jun 29, 2001 | 208 |
| -44.02% | Oct 5, 2012 | 299 | Dec 13, 2013 | 217 | Oct 24, 2014 | 516 |
| -37.11% | Feb 12, 2002 | 112 | Jul 23, 2002 | 199 | May 7, 2003 | 311 |
| -36.15% | Nov 29, 2019 | 78 | Mar 23, 2020 | 110 | Aug 27, 2020 | 188 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading data...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Edwards Lifesciences Corporation over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Earnings Per Share
The chart presents the Earnings Per Share (EPS) performance of Edwards Lifesciences Corporation, comparing actual results with analytics estimates. The company has exceeded analyst expectations for EPS in the past quarter, achieving a 7.5% positive surprise.
Valuation
The Valuation section provides an overview of how Edwards Lifesciences Corporation is priced in the market compared to other companies in the Medical Devices industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for EW, comparing it with other companies in the Medical Devices industry. Currently, EW has a P/E ratio of 32.3. This P/E ratio is in line with the industry average, suggesting the stock may be fairly valued relative to its earnings.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for EW compared to other companies in the Medical Devices industry. EW currently has a PEG ratio of 4.4. This PEG ratio is higher than the industry average, which may suggest the stock is overvalued relative to its expected earnings growth.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for EW relative to other companies in the Medical Devices industry. Currently, EW has a P/S ratio of 8.3. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for EW in comparison with other companies in the Medical Devices industry. Currently, EW has a P/B value of 4.5. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |